Protagonist Therapeutics, Inc.

NASDAQ:PTGX

Biotechnology

Healthcare
$127.16 +1.54%

+$1.72 today

Market cap
$8.30B
Beta
1.83
P/E (TTM)
-64.2
EPS (TTM)
-$1.76
52W Low $49.38High $114.00

Volume 0.43M

Average 0.72M

PTGX Income Tax Expense

Income taxes recognized for the period, including current and deferred tax.

Protagonist Therapeutics, Inc.NASDAQ: PTGX

Income Tax Expense · Q2 FY2026 · quarter ended Jun 2026

Income tax expense growth accelerates

Q2 FY2026 income tax expense of $2.27M rose 1216.9% year over year, ahead of the -18.0% change in trailing-twelve-month income tax expense.

Context

  • Income tax expense amounted to 1.8% of revenue in FY2025, up 0.8 pp from a year earlier.
  • Income tax expense increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +1216.9% holds above the trailing-twelve-month pace of -18.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$2.27M+250.8% QoQ
Last fiscal yearDec 2025
$838K-80.1% YoY
LTMJun 2026
$1.43M-18.0% YoY
Income Tax Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1216.9%——
1 year-80.1%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Tax Expense history

USD · from the income statement

Latest · FY2025
838K USD
Year-over-year change
-80.1%

Income Tax Expense vs competitors

How PTGX compares with its peers on the latest reported figures

  • PTGX's LTM Jun 2026 income tax expense of $1.43M is the highest of the 7 companies compared; the peer median is $0.
  • Its year-over-year change of -18.0% is the 3rd highest of 5, against a peer median of +35.3%.
  • Income tax expense amounts to 0.5% of revenue for PTGX, versus a peer median of 0.0%.
PTGX Competitors Peer median
Income Tax Expense for PTGX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PTGXProtagonist Therapeutics, Inc.LTM Jun 2026$1.43M -18.0%—0.5%
IRONDisc Medicine, Inc.LTM Sep 2026$317K -29.4%——
ANABAnaptysBio, Inc.LTM Mar 2026$160K +240.4%+89.8%0.1%
SYRESpyre Therapeutics, Inc.LTM Sep 2026$0 +100.0%—0.0%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$0 ——0.0%
IMUXImmunic, Inc.LTM Mar 2026$0 ———
IMVTImmunovant, Inc.LTM Sep 2026-$1.29M -157.6%+188.0%18.2%
ODTXOdyssey Therapeutics, Inc.—— ———
Peer median (excluding PTGX) $0+35.3%+138.9%0.0%

Competitors are the stored peer set for PTGX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue27.36M26.58M60M434.43M46.02M
Cost of Revenue00001.23M
Gross Profit27.36M26.58M60M434.43M44.79M
Gross Margin100.0%100.0%100.0%100.0%97.3%
Research & Development126.01M126.22M120.16M138.13M159.29M
Selling, General & Admin27.2M31.74M33.49M43.46M44.85M
Operating Expenses153.2M157.95M153.65M181.59M202.92M
Depreciation & Amortization2.78M3.37M3.31M2.96M1.28M
EBITDA(122.78M)(124.02M)(75.64M)282.37M(128.03M)
EBITDA Margin-448.8%-466.6%-126.1%65.0%-278.2%
Operating Income(125.85M)(131.37M)(93.65M)252.84M(158.13M)
Operating Margin-460.0%-494.2%-156.1%58.2%-343.6%
Interest Income443K4.06M14.9M26.32M28.79M
Interest Expense00000
Other Income / Expenses294K3.98M14.7M26.57M28.82M
Income Before Tax(125.55M)(127.39M)(78.96M)279.41M(129.31M)
Pre-Tax Margin-458.9%-479.3%-131.6%64.3%-281.0%
Income Tax Expense0004.22M838K
Net Income(125.55M)(127.39M)(78.96M)275.19M(130.15M)
Net Margin-458.9%-479.3%-131.6%63.3%-282.8%
EPS (Basic)(2.65)(2.52)(1.39)4.47(2.05)
EPS (Diluted)(2.65)(2.52)(1.39)4.23(2.05)
Weighted Avg Shares46.32M49.04M56.76M61.57M63.57M
Weighted Avg Shares (Diluted)46.32M49.04M56.76M65.08M63.57M

Protagonist Therapeutics, Inc.

NASDAQ:PTGX

Intrinsic Alpha fair value

Locked

Current Price

$127.16

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.